'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning.
The majority of patients with relapsed or refractory Hodgkin's lymphoma (HL) will not be cured with standard therapy. Relapse rates remain high even after autologous stem cell transplantation (SCT), particularly for patients with high-risk disease. Allogeneic SCT offers several potential advantages for patients with HL. It is feasible when autologous stem cells are not available and stem cell grafts will be tumor free. Perhaps a more important advantage is the potential to generate a graft-versus-Hodgkin's lymphoma (GVHL) effect. Unfortunately, although allogeneic SCT may cure some HL patients, treatment-related mortality has been unusually high, and superior survival, when compared to autologous SCT, has not been demonstrated. Nonmyeloablative conditioning and allogeneic SCT may induce a direct GVHL reaction with less conditioning regimen-related toxicity and ultimately may have the potential to improve cure rates and survival for advanced HL patients.
Bone Marrow and Stem Cell Transplant Program, Division of Hematology-Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA.
D L
DL
Porter
E A
EA
Stadtmauer
H M
HM
Lazarus
D006086:Graft vs Host Disease / Q000628:therapy; D020350:Graft vs Tumor Effect; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D017710:Lymphocyte Transfusion / Q000379:methods